Morgan Stanley lowered the firm’s price target on Alector (ALEC) to 75c from $1.50 and keeps an Underweight rating on the shares. The firm, which is updating its model to account for the Phase 3 INFRONT-3 trial evaluating latozinemab failing to meet its co-primary endpoint, now includes revenues for AL101 in Alzheimer’s disease but in a “heavily discounted” fashion, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector’s Strategic and Financial Challenges Prompt Sell Rating Amid Clinical Setbacks
- Alector’s Strategic Shift to ABC Platform: Promising CNS Delivery and Neurodegenerative Disease Solutions
- Cautious Outlook on Alector Amid Strategic Shift and Uncertain Clinical Prospects
- Alector, Inc. Reports Q3 2025 Financial Results
- Cautious Hold on Alector Amid Strategic Shift and Long-term Focus